JPRN-UMIN000000610已完成2 期
Antiestrogen vs aromatase inhibitor after chemotherapy for adjuvant setting: Efficacy of endocrine therapy after chemotherapy in postoperative adjuvant therapy for breast cancer - Antiestrogen vs aromatase inhibitor after chemotherapy for adjuvant setting: Efficacy of endocrine therapy after chemotherapy in postoperative adjuvant therapy for breast cancer
Japan Breast Cancer Research Network0 个研究点目标入组 240 人开始时间: 2007年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1) Pregnant or breast feeding. (2) Bilateral or inflammatory breast cancer. (3) Multiple cancers. (4) Life-threatening metastases. (5) History of serious hypersensitivity. (6) Judged ineligible for the study by the study doctor.
研究者
相似试验
终止
2 期
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast CancerBreast NeoplasmsNCT00437359Japan Breast Cancer Research Network240
已完成
不适用
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer CHAARTED-C61 Malignant neoplasm of prostateMalignant neoplasm of prostateC61PER-081-08EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
已完成
不适用
se of non steroidal aromatase inhibitors in treatment of patients with early invasive hormone-dependent breast cancer in everyday clinical practiceEarly invasive hormone-dependent breast cancerMalignant neoplasm of breastCancerISRCTN95653203PLIVA Croatia Ltd. (Croatia)500
进行中（未招募）
不适用
Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasmsWomen with oestrogen receptor and/or progesterone receptor positive (ER/PR+ve) potentially hormone responsive recurrent or metastatic gynaecological cancer including selected patients with epithelial ovarian cancer, endometrial cancers, miscellaneous sarcomas and sex cord stromal tumours of the ovaryEUCTR2011-003192-11-BEniversity of Sydney
Unknown
3 期
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast CancerNeoadjuvant TherapyNCT02769104Zhejiang Cancer Hospital120